Unraveling Ibogaine's Mechanisms of Action: A Neuro­pharmacological Perspective

I. Introduction

Ibogaine, a naturally occurring psychoactive indole alkaloid, is primarily derived from the root bark of Tbernanthe iboga, a shrub indigenous to West Africa . For centuries, this plant has held cultural significance, playing a central role in the religious and spiritual ceremonies of indigenous populations, particularly within the Bwiti tradition of Gabon . The psychoactive properties of Tabernanthe iboga were first brought to the attention of the Western world in the late 19th century, leading to the isolation of ibogaine as a distinct chemical entity in the early 20th century . Initially marketed in France under the trade name Lambarène during the 1930s, ibogaine was used for its stimulant effects . However, a pivotal observation in the 1960s by Howard Lotsof revealed the compound’s potential to interrupt opioid dependence, marking the beginning of intense scientific interest in its anti-addictive properties.  

The subsequent decades have witnessed a surge in research exploring the therapeutic potential of ibogaine, particularly in the context of substance use disorders (SUDs), with a significant focus on opioid use disorder (OUD). Despite promising anecdotal reports and observational studies highlighting ibogaine’s ability to reduce drug cravings, mitigate withdrawal symptoms, and decrease the likelihood of relapse across a range of substances including opioids, stimulants, alcohol, and nicotine, its precise mechanisms of action remain a subject of ongoing investigation.

The pharmacological profile of ibogaine is remarkably complex, characterized by its interactions with a multitude of neurotransmitter systems and receptor targets within the central nervous system . This polypharmacological nature presents both a challenge and an opportunity for understanding its therapeutic effects. The intricate interplay of these interactions likely underlies the unique and often long-lasting impact of ibogaine on addictive behaviors. Therefore, a comprehensive understanding of these mechanisms is crucial for evaluating its potential as a treatment for addiction and for guiding future research aimed at optimizing its use and developing safer, more targeted therapeutic agents. The historical trajectory of ibogaine, from its traditional use in spiritual practices to its modern scientific investigation for addiction treatment, underscores the importance of bridging traditional knowledge with rigorous scientific inquiry. The initial observations of its psychoactive properties by indigenous cultures laid the groundwork for subsequent scientific exploration. Lotsof’s serendipitous discovery of its anti-addictive effects then catalyzed further research into the neurobiological basis of these observations. Modern science seeks to elucidate the specific molecular mechanisms responsible for ibogaine’s effects, aiming to translate anecdotal evidence and traditional uses into evidence-based therapeutic applications. The fact that ibogaine interacts with numerous neurochemical systems simultaneously suggests that its therapeutic efficacy likely stems from a coordinated modulation of these systems, rather than a singular action on a specific target. This multifaceted approach could be particularly relevant for treating the complex neurobiological underpinnings of addiction, which involve disruptions across multiple brain circuits and neurotransmitter pathways.

II. Interaction with Opioid Receptor Systems

Research indicates that ibogaine exhibits binding affinity for all three major subtypes of opioid receptors: mu (μ), kappa (κ), and delta (δ) . These receptors play critical roles in pain modulation, reward processing, and the development of opioid dependence. Studies suggest that ibogaine acts as a weak antagonist at the μ-opioid receptor . This antagonistic activity is thought to contribute to the reduction of opioid cravings and the facilitation of opioid detoxification . By partially blocking the effects of opioids at these receptors, ibogaine may help to attenuate withdrawal symptoms without producing the euphoric or analgesic effects associated with opioid agonists.Conversely, ibogaine is suspected to act as an agonist at the κ-opioid receptor . Activation of this receptor subtype has been linked to various effects, including analgesia, antidepressant activity, anti-addictive properties, and neuroprotection . The κ-opioid receptor system is also implicated in the dysphoric effects of withdrawal from some drugs, and ibogaine’s agonism at this site might play a complex role in its overall impact on addiction . Interestingly, the primary metabolite of ibogaine, noribogaine, demonstrates a higher affinity for both κ and μ opioid receptors compared to the parent compound. Noribogaine itself acts as a weak antagonist at the μ-opioid receptor.

The precise nature of ibogaine’s interaction with the μ-opioid receptor has been a subject of some debate. While some early studies suggested high-affinity binding to a μ-opioid agonist site, subsequent research, employing functional assays such as agonist-stimulated guanosine-5´-O-(γ-thio)-triphosphate (GTPγS) binding, indicates that ibogaine and noribogaine do not appear to function as orthosteric agonists at this receptor. These studies found that ibogaine and its metabolite acted as antagonists at the μ-opioid receptor in rat thalamic membranes. This suggests that the observed effects of ibogaine on opioid withdrawal are likely mediated through alternative mechanisms rather than direct activation of μ-opioid receptors in the same way as traditional opioid agonists like morphine or methadone.  

Further evidence supporting a unique interaction with the opioid system comes from studies showing that ibogaine and noribogaine can attenuate tolerance to morphine analgesia in animal models. This effect appears to involve signaling pathways specifically linked to the μ-opioid receptor, as it is observed with morphine but not with delta or kappa opioid agonists. The ability to reduce opioid tolerance without exhibiting typical μ-opioid agonist effects highlights a distinctive mechanism of action on the opioid system. This modulation could be a critical factor in ibogaine’s effectiveness in treating opioid addiction, potentially by resensitizing individuals to the effects of opioids and thereby reducing the severity of withdrawal symptoms and the drive to seek the drug to overcome tolerance.

III. Modulation of the Serotonin System

A significant aspect of ibogaine’s pharmacological profile is its potent inhibitory action on the serotonin transporter (SERT) . Both ibogaine and its metabolite, noribogaine, are strong serotonin reuptake inhibitors . The serotonin system plays a crucial role in regulating mood, emotion, and reward pathways, and its modulation is a common mechanism of action for antidepressant medications known as selective serotonin reuptake inhibitors (SSRIs). Similar to SSRIs, ibogaine and noribogaine increase the levels of serotonin in the synaptic cleft by blocking its reuptake into presynaptic neurons . Notably, ibogaine acts as a non-competitive inhibitor of SERT . This means that it does not compete with serotonin for the same binding site on the transporter, and its inhibitory effect is not simply overcome by higher concentrations of serotonin. This non-competitive inhibition is suspected to contribute to the antidepressant effects observed with ibogaine and may play a role in improving negative mood states often experienced during post-acute withdrawal from addictive substances .  

Interestingly, noribogaine exhibits a higher affinity for the serotonin transporter compared to ibogaine . This suggests that noribogaine may play a more prominent role in the serotonergic effects of ibogaine, particularly given its longer half-life in the body . Cryo-electron microscopy studies have revealed a unique mechanism by which ibogaine inhibits SERT. Unlike typical SSRIs or cocaine, which bind to the outward-facing conformation of the transporter, ibogaine stabilizes a unique inward-facing conformation. This distinct mechanism of inhibition could potentially lead to different downstream effects on serotonin signaling compared to conventional antidepressants, possibly contributing to ibogaine’s unique therapeutic profile. In vivo microdialysis studies have shown that both ibogaine and noribogaine can elevate serotonin levels in the nucleus accumbens, a key brain region involved in reward and motivation, with noribogaine demonstrating greater efficacy in this regard. The potent inhibition of SERT by ibogaine and especially noribogaine suggests a substantial involvement of the serotonin system in mediating the overall effects of ibogaine. This modulation could contribute to its ability to influence reward pathways, regulate emotional states, and potentially alleviate depressive symptoms often associated with addiction and withdrawal. The unique non-competitive mechanism of SERT inhibition by ibogaine, distinct from traditional antidepressants, may underlie some of its specific therapeutic actions and could offer potential advantages for addressing certain aspects of addiction or co-occurring mood disorders that are not effectively treated by conventional SSRIs.

IV. Influence on the Dopamine System

Ibogaine also interacts with the dopamine system, another critical neurotransmitter pathway involved in reward, motivation, and motor control . Research has demonstrated that ibogaine binds to the dopamine transporter (DAT) . The dopamine transporter is responsible for removing dopamine from the synaptic cleft, and its inhibition leads to increased dopamine levels. Studies have shown that ibogaine exerts biphasic effects on dopamine levels, suggesting a complex interaction with this system . Initially, both ibogaine and its metabolite, noribogaine, have been shown to decrease extracellular levels of dopamine in the nucleus accumbens acutely . However, ibogaine’s interaction with DAT has been shown to result in adaptive dopamine signaling and a restoration of functional activity in brain regions associated with opioid addiction and reward processing, such as the ventral tegmental area (VTA) and nucleus accumbens .Pretreatment with ibogaine has been observed to block morphine-induced dopamine release and the associated locomotor hyperactivity in animal models. Conversely, it enhances similar effects of stimulant drugs like cocaine and amphetamine . This differential modulation of dopamine responses to different classes of drugs of abuse suggests a sophisticated mechanism by which ibogaine might help to normalize dysregulated dopamine signaling in the context of addiction. Furthermore, ibogaine has been shown to stimulate the production of glial-derived neurotrophic factor (GDNF) . GDNF is a neurotrophic factor that has been identified as a potential treatment target for addiction due to its ability to promote the survival and function of dopamine neurons, even restoring damaged ones . Studies in rodents have indicated that ibogaine administration increases GDNF expression in brain regions like the VTA, which hosts the cell bodies of dopaminergic neurons . This increase in GDNF may contribute to the long-lasting anti-addictive effects of ibogaine by promoting neuroplasticity and repairing dopamine circuits affected by chronic drug use.

Interestingly, research has also shown that ibogaine and noribogaine possess the ability to correct folding defects in the dopamine transporter . Folding-deficient mutations in DAT are associated with dopamine transporter deficiency syndrome (DTDS), a severe neurological disorder. The pharmacochaperoning action of ibogaine and noribogaine on DAT highlights a potential therapeutic application beyond addiction, suggesting a role in treating conditions characterized by DAT dysfunction. The multifaceted interaction of ibogaine with the dopamine system, involving direct effects on DAT, modulation of dopamine release, and the upregulation of GDNF, suggests a complex mechanism for influencing reward pathways and potentially reversing some of the neuroadaptations associated with addiction. The initial reduction in dopamine levels followed by the potential for long-term restoration through GDNF could be a key aspect of how ibogaine disrupts addictive behaviors and promotes recovery. The ability of ibogaine and noribogaine to rescue folding-deficient DAT further underscores the broad therapeutic potential of these compounds, extending beyond addiction to other neurological disorders involving the dopamine system.

V. NMDA Receptor Antagonism

Another significant mechanism of action for ibogaine involves its antagonism of the N-methyl-D-aspartate (NMDA) receptor . NMDA receptors are a subtype of glutamate receptors that play a crucial role in synaptic plasticity, learning, and memory. They are also implicated in the development of drug tolerance, dependence, and withdrawal. Ibogaine’s ability to block NMDA receptors is associated with the mitigation of withdrawal symptoms, a reduction in opioid reward, and decreased drug-seeking behaviors . NMDA receptor antagonism has also been implicated in the treatment of depression, and ibogaine’s action at this receptor might contribute to its observed effects on mood. Research suggests that ibogaine can act as a safe NMDA antagonist even at relatively high dosages, including those that induce hallucinations . This property could be particularly beneficial in reducing or preventing excitotoxic brain damage resulting from conditions such as stroke, cardiac arrest, trauma, or other forms of neuronal injury or degeneration. The relative safety of ibogaine at these dosages is thought to be due to its concurrent antagonist activity at neuronal sigma receptors. The NMDA receptor antagonism exhibited by ibogaine likely plays a critical role in its anti-addictive effects by disrupting the glutamatergic neurotransmission that contributes to drug craving and withdrawal. This mechanism is shared with other therapeutic agents like ketamine, which has shown efficacy in mitigating opioid withdrawal symptoms and treating major depressive disorder, suggesting a common pathway for these effects. The finding that ibogaine can act as a relatively safe NMDA antagonist with potential for neuroprotection against excitotoxicity expands its potential therapeutic applications beyond addiction to include conditions involving neuronal damage, such as stroke and traumatic brain injury.

VI. Interaction with Nicotinic Receptors

Ibogaine has been shown to modulate nicotinic acetylcholine receptors (nAChRs), particularly acting as a noncompetitive antagonist at the α3β4 subtype . Nicotinic receptors are ligand-gated ion channels that play a role in various physiological processes, including neurotransmission, learning, and reward. The α3β4 subtype is specifically implicated in nicotine addiction and opioid withdrawal symptoms. Antagonism of this receptor by ibogaine is thought to contribute to the attenuation of opioid withdrawal symptoms. By blocking these receptors, ibogaine may help to reduce the severity of physical and psychological discomfort associated with opioid cessation.

Furthermore, studies suggest that the blockade of α3β4 nicotinic receptors by ibogaine and its analog 18-methoxycoronaridine (18-MC) may indirectly contribute to their anti-addictive effects by dampening dopamine responses to addictive drugs . This indirect modulation of the dopamine system could reduce the reinforcing properties of various substances of abuse, thereby decreasing the motivation to seek and use drugs. The specific antagonism of α3β4 nicotinic receptors by ibogaine suggests a targeted mechanism for alleviating opioid withdrawal and potentially treating nicotine addiction. This selectivity could offer advantages over non-specific nicotinic antagonists that might have broader and less desirable side effects. The indirect reduction of dopamine responses to addictive substances through α3β4 receptor blockade indicates a potential mechanism by which ibogaine can diminish the rewarding effects of drugs, contributing to its broad anti-addictive properties across different classes of substances.

VII. Sigma Receptor Modulation

Research indicates that ibogaine possesses an affinity for sigma receptors, particularly the sigma-2 (σ2) subtype, and to a lesser extent, the sigma-1 (σ1) subtype . Sigma receptors are unique intracellular chaperone proteins or signal transduction amplifiers that are implicated in a variety of physiological and pathological processes, including inflammation and pain states . Ibogaine’s binding to sigma receptors, especially σ2 receptors, has been associated with the modulation of inflammatory responses . Additionally, the NMDA antagonism exhibited by ibogaine may also contribute to its anti-inflammatory and antinociceptive (pain-relieving) effects .

However, the interaction of ibogaine with sigma-2 receptors has also been potentially linked to its neurotoxic effects observed in some preclinical studies . While the precise role of sigma receptors in ibogaine’s overall pharmacology is still being elucidated, their involvement suggests another layer of complexity to its mechanisms of action. Sigma receptors have been implicated in various conditions, including cancer, pain, neuropsychiatric disorders, and substance use disorders. Interestingly, ibogaine shows a notable selectivity for the σ2 receptor over the σ1 receptor . This differential selectivity might explain some of the specific effects of ibogaine compared to other drugs that interact with the sigma system, as these two subtypes have distinct functions and pharmacological profiles. While ibogaine’s interaction with sigma receptors may contribute to its anti-inflammatory and analgesic properties, the potential link to neurotoxicity through σ2 receptors underscores the importance of carefully considering its safety profile and dosage. The preferential binding to σ2 receptors over σ1 receptors may also contribute to the unique pharmacological profile of ibogaine.

VIII. Effects on Neurotrophic Factors (GDNF and BDNF)

A growing body of evidence highlights ibogaine’s ability to influence the expression of neurotrophic factors, particularly glial-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF). These proteins play critical roles in the survival, growth, differentiation, and plasticity of neurons in the brain. GDNF has been identified as a promising therapeutic target for addiction due to its capacity to protect and even restore damaged dopamine neurons, which are often compromised in individuals with substance use disorders. Studies have shown that ibogaine administration stimulates the production of GDNF in the brain. Specifically, research in rodents has demonstrated that ibogaine modifies the expression of both GDNF and BDNF in brain regions involved in the mesocorticolimbic and nigral dopaminergic circuits, which are central to reward and addiction.

In rats, a single administration of ibogaine has been shown to upregulate GDNF selectively in the VTA and substantia nigra (SN) in a dose-dependent manner . Similarly, ibogaine elicited a large increase in the expression of BDNF in the nucleus accumbens (NAcc), SN, and prefrontal cortex (PFC) . These findings suggest that ibogaine can exert region-specific effects on neurotrophic factor expression, potentially contributing to its long-lasting impact on addictive behaviors. Notably, there is evidence linking ibogaine’s effects on alcohol self-administration in rats to the release of GDNF in the VTA . Microinjection of ibogaine into the VTA resulted in a sustained reduction in ethanol consumption, an effect that was attenuated by blocking GDNF signaling .

The upregulation of GDNF and BDNF by ibogaine in key brain regions implicated in reward and addiction offers a potential explanation for its enduring anti-addictive effects. These neurotrophic factors are known to promote neuronal survival, growth, and synaptic plasticity, which could facilitate the reversal of neuroadaptations induced by chronic drug exposure. The observed dose-dependent and brain region-specific changes in GDNF and BDNF expression suggest a complex and nuanced mechanism of action. Different dosages of ibogaine might preferentially influence specific neural circuits, potentially contributing to varying therapeutic outcomes or side effects. This highlights the importance of further research to determine the optimal dosage and administration strategies to maximize the therapeutic benefits of ibogaine while minimizing potential risks.

IX. Impact on Myelination

Emerging research suggests that ibogaine may also influence myelination, the process of forming a myelin sheath around nerve fibers that is crucial for efficient neural communication. A recent study investigated the effects of ibogaine administration on myelination markers in the internal capsule of Sprague Dawley rats following repeated morphine administration . The researchers examined the expression of 2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) and myelin basic protein (MBP), two key markers of myelination. The findings revealed that ibogaine administration following repeated morphine administration led to a significant upregulation of both CNP and MBP mRNA and protein expression . This suggests that ibogaine has the potential to upregulate genes and proteins involved in the process of remyelination after opioid use.

Interestingly, opioid addiction has been associated with demyelination and decreased white matter tract connectivity in the brain . The ability of ibogaine to promote the expression of myelination markers in the context of morphine exposure indicates a novel mechanism by which it might help to reverse some of the neurological damage associated with chronic opioid use. Furthermore, the kappa opioid receptor, with which ibogaine interacts, has been shown to influence remyelination through oligodendrocytes, the cells responsible for producing myelin. Ibogaine’s partial agonist activity at the kappa opioid receptor might therefore be linked to its observed effects on myelination. The discovery that ibogaine can upregulate myelination markers in the setting of morphine administration suggests a previously unrecognized mechanism by which it might contribute to recovery from opioid addiction. This finding warrants further investigation to fully understand ibogaine’s role in promoting white matter integrity and its potential implications for treating substance use disorders. The potential involvement of the kappa opioid receptor in this process further highlights the complex interplay of ibogaine’s various pharmacological actions.  

X. Psychedelic Effects and Potential Mechanisms

Beyond its direct neuropharmacological actions on various receptor systems, ibogaine is well-known for its profound psychedelic effects. These effects are often described as oneirogenic, inducing dream-like states of consciousness accompanied by vivid imagery, autobiographical recall, and intense introspection. Many individuals who undergo ibogaine treatment for addiction report gaining significant insights into the underlying psychological factors contributing to their addictive behaviors. This introspective phase is often considered a crucial aspect of ibogaine’s therapeutic potential, allowing individuals to confront past traumas, understand maladaptive patterns, and develop a renewed sense of self and motivation for recovery.

The precise neurobiological mechanisms underlying ibogaine’s psychedelic effects are not fully understood but are likely mediated through a complex interplay of its various pharmacological actions. It is hypothesized that the combination of kappa opioid receptor agonism, NMDA receptor antagonism, and modulation of serotonergic transmission plays a significant role in producing these unique subjective experiences. For instance, the agonism at kappa opioid receptors is known to produce dissociative and hallucinogenic effects in some compounds. Similarly, NMDA receptor antagonists can induce altered states of consciousness. The modulation of serotonin levels by ibogaine could also contribute to its psychedelic properties, as many classic psychedelic drugs exert their effects through the serotonin system . While the primary focus of this report is on the direct neuropharmacological mechanisms, the psychedelic experience induced by ibogaine appears to be an integral part of its therapeutic efficacy for addiction. The insights and emotional processing facilitated during this phase may contribute significantly to long-term behavioral changes and the prevention of relapse. The proposed interaction between kappa opioid agonism, NMDA antagonism, and serotonergic transmission in mediating these effects underscores the synergistic nature of ibogaine’s polypharmacology. Further research into how these different receptor systems interact to produce the characteristic psychedelic experience is essential for optimizing its therapeutic use and potentially developing safer analogs that retain the beneficial psychological effects while minimizing risks.

XI. Conclusion

In conclusion, ibogaine presents a remarkably complex and multifaceted pharmacological profile. Its mechanisms of action involve interactions with a wide array of neurotransmitter systems, including opioid, serotonin, dopamine, NMDA, nicotinic, and sigma receptors . Furthermore, ibogaine influences the expression of neurotrophic factors like GDNF and BDNF and has shown potential to impact myelination processes . This intricate polypharmacology likely underlies ibogaine’s reported efficacy in treating substance use disorders by targeting the diverse neurochemical pathways involved in addiction and dependence. By acting as a weak mu opioid antagonist, a suspected kappa opioid agonist, a potent serotonin reuptake inhibitor, a dopamine modulator, an NMDA antagonist, and a nicotinic receptor antagonist, ibogaine simultaneously addresses various aspects of addiction, including craving, withdrawal, and reward processing. The upregulation of neurotrophic factors and the potential promotion of remyelination further suggest long-term neuroadaptive effects that could contribute to sustained recovery.

As research continues to unravel the complex mechanisms of action of ibogaine, its potential to transform the treatment of addiction and other neuropsychiatric conditions becomes increasingly apparent.  

References

1. HO-6-slides-per-page-Final_Ibogaine-Pharmacology.pdf. pharmacy.media.uconn.edu.  
2. HO-6-slides-per-page-Final_Ibogaine-Pharmacology.pdf. pharmacy.media.uconn.edu.  
3. Ibogaine administration following repeated morphine administration upregulates myelination markers 2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats. frontiersin.org.
4. Ibogaine administration following repeated morphine administration upregulates myelination markers 2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats. frontiersin.org.
5. Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation. pmc.ncbi.nlm.nih.gov.
6. Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation. pmc.ncbi.nlm.nih.gov.  
7. Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation. pmc.ncbi.nlm.nih.gov.  
8. Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation. pubmed.ncbi.nlm.nih.gov.  
9. Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation. pmc.ncbi.nlm.nih.gov.  
10. High affinity ibogaine binding to a mu opioid agonist site. pubmed.ncbi.nlm.nih.gov.  
11. Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport. pubmed.ncbi.nlm.nih.gov.  
12. Ibogaine, a Noncompetitive Inhibitor of Serotonin Transport, Acts by Stabilizing the Cytoplasm-facing State of the Transporter. researchgate.net.  
13. Ibogaine, an alkaloid extracted from Tabemanthe iboga, is being studied as a potential long-acting treatment for oploid and stimulant abuse as well as for alcoholism and smoking. pubmed.ncbi.nlm.nih.gov.  
14. Ibogaine, an alkaloid extracted from Tabemanthe iboga, is being studied as a potential long-acting treatment for oploid and stimulant abuse as well as for alcoholism and smoking. pubmed.ncbi.nlm.nih.gov.  
15. Ibogaine, an alkaloid extracted from Tabemanthe iboga, is being studied as a potential long-acting treatment for oploid and stimulant abuse as well as for alcoholism and smoking. pubmed.ncbi.nlm.nih.gov.  
16. Ibogaine, an alkaloid extracted from Tabemanthe iboga, is being studied as a potential long-acting treatment for oploid and stimulant abuse as well as for alcoholism and smoking. pubmed.ncbi.nlm.nih.gov.  
17. Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters | ACS Pharmacology & Translational Science. pubs.acs.org.  
18. US5629307A – Use of ibogaine to prevent or reduce brain damage. patents.google.com.  
19. Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release. pubmed.ncbi.nlm.nih.gov.  
20. Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. frontiersin.org.  
21. Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits – PMC. ncbi.nlm.nih.gov.  
22. Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. frontiersin.org.  
23. Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. pubmed.ncbi.nlm.nih.gov.  
24. Ibogaine administration following repeated morphine administration upregulates myelination markers 2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats. frontiersin.org.  
25. (PDF) Ibogaine administration following repeated morphine administration upregulates myelination markers 2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats. researchgate.net.  
26. Ibogaine administration following repeated morphine administration upregulates myelination markers 2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats – PMC. ncbi.nlm.nih.gov.  
27. Ibogaine administration following repeated morphine administration upregulates myelination markers 2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats. pubmed.ncbi.nlm.nih.gov.  
28. Ibogaine induces neuroplasticity and neurocircuitry changes in two MS patients: A case report. frontiersin.org.  
29. The Sigma-2 Receptor: A Promising Target for Cancer Therapy and Neurodegenerative Disorders. mdpi.com.  
30. The psychedelic iboga alkaloid congener, tabernanthalog, promotes sustained structural plasticity and antidepressant-like effects via the 5-HT 2A receptor. biorxiv.org.